# CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication

> **NCT07344506** · PHASE4 · RECRUITING · sponsor: **Dow University of Health Sciences** · enrollment: 942 (estimated)

## Conditions studied

- H. Pylori Gastrointestinal Disease
- H.Pylori Infection
- H.Pylori Eradication Rate

## Interventions

- **DRUG:** Arm 1: Dexlansoprazole + Levofloxacin-Based Triple Therapy
- **DRUG:** Arm 2: Lansoprazole + Levofloxacin-Based Triple Therapy
- **DRUG:** Arm 3: Vonoprazan + Levofloxacin-Based Triple Therapy

## Key facts

- **NCT ID:** NCT07344506
- **Lead sponsor:** Dow University of Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2026-05-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 942 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07344506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07344506, "CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07344506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*